Home / Cancer and immune system / Daclizumab
ATC L04AC01 · Interleukin Inhibitors
Daclizumab shortage
As of 2 Nov 2026, Daclizumab has a reported shortage in 1 of the 15 countries we track (Canada), covering 1 product from 1 company.
Countries1/15
Products1packs or presentations
Companies11 listed
Short since–
Earliest returnnot givencompany estimate
Main reasonNot stated
United StatesNo reported shortageCanada1 product shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageAustraliaNo reported shortage
Which companies are short
products short, all countriesListed: Biogen BIIB · Nasdaq
Compared with similar medicines
ATC group L04AC · Interleukin InhibitorsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CA | ZINBRYTA (One prefilled syringe for injection) discontinuation | BIOGEN CANADA INC | not given | not given | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.